Eurofins history

Stanaway earned his Bachelor of Science degree from Willamette University, Salem Oregon in 1988 with a minor in Environmental Science.

1989: Eurofins expands its technology to include the testing of non-alcoholic beverages and flavorings.

By 1991, Eurofins's sales had risen to EUR 1.4 million.

1993: The company creates a sales subsidiary in the United States.

In 1997, the company made its first acquisition, buying up Nutrition International and Product Safety Labs in the United States.

Eurofins boosted its U.K. presence in 1998, adding three more companies that were subsequently merged into its existing subsidiary to form Eurofins Scientific Ltd.

Similarly, in 1999, Eurofins acquired the Alpha Chemical and Biomedical Laboratories, based in California, adding its capacity for analyzing botanicals and nutraceuticals.

By the end of 2000, the company's acquisitions included Celab AG in Switzerland and Gesellschaft für Arbeitsplatz- und Umweltanalytik (GfA) mbH, operating in Munster, Germany, and Orleans, France.

Pinaud, Olivier, "'Nous sommes optimistes pour la suite de l'année.'" Investir, August 29, 2001.

The company had also begun developing an outsourcing arm, taking over the research, testing, and analysis operations for third parties, including a nutritional assay outsourcing agreement with Glon Sanders reached in 2002.

With the 2003 launch of Aller-Gene, the market's first multi-allergen PCR (polymerase chain reaction) screening test, Eurofins positioned itself as a "one-stop shop" for testing services and procedures.

Doctor Michael Berg joined Eurofins EMLab P&K in 2005 and worked as Department Manager, Regional Director and Technical Director.

By 2008, the Group had grown to over 8,000 staff, and more than 150 laboratories in 29 countries.

Turning Data into Information by Richard Burrows 2010

In 2012, the Group celebrated 15 years since its IPO and this milestone coincided with achieving its ambition of becoming a billion euro annual revenue business, one year before its objective.

Later developments included the Animal ID DNA Test – quickly validated as a routine test by Eurofins in the wake of the horsemeat crisis in 2013, making Eurofins one of the first companies able to verify at high throughput the absence of undeclared horsemeat in a wide range of food products.

Eurofins used these funds in a focused manner and only raised equity again more than 15 years later in 2016 when its revenues already exceeded EUR 2 billion.

An operational goal was also set to develop the laboratory and IT infrastructure of a global leader in Testing for Life by 2020.

Over €6.7 billion in annualised revenues in 2021